J&J Prevails as Stelara Buyers’ Antitrust Claims Are Dropped

A federal judge entered a final judgment that allows Johnson & Johnson to shed claims from third-party purchasers of the Stelara drug.

The judgment came in a Tuesday order by the US District Court for the Eastern District of Virginia after plaintiff Carefirst of Maryland Inc. jointly agreed with J&J that a series of December and January orders effectively disposed of the claims.

The third-party purchasers previously won partial class action status.

Carefirst in 2023 alleged that J&J unlawfully delayed competing generic versions of the Stelara drug, which is used to treat Crohn’s disease, causing third-party buyers to pay inflated ...